Target intelligence / Profile preview

Cohesin subunit SA-3 (STAG3)

Target: STAG3
Molecular classification: Meiosis-specific cohesin complex subunit, Structural maintenance of chromosomes protein complex component, Other (not a receptor, enzyme, transporter, or transcription factor)

Overview

Cohesin subunit SA-3 (STAG3) is a meiosis-specific component of the cohesin complex, a multi-subunit protein machinery essential for the stable cohesion of sister chromatids after DNA replication, especially during meiosis[6]. This subunit is uniquely expressed in gametogenic cells and is crucial for homologous chromosome pairing, synapsis, recombination, and segregation in both spermatogenesis and oogenesis[4][5][7]. Loss-of-function mutations in STAG3 cause infertility in both sexes due to meiotic arrest, disrupted chromosome axis formation, and synapsis defects. Beyond its canonical role in meiosis, recent studies suggest that STAG3 may also regulate exit from pluripotency in stem cells via post-transcriptional mechanisms, expanding its functional repertoire beyond chromosome cohesion[2]. STAG3 is not currently a therapeutic target but is an important diagnostic marker for certain heritable infertility syndromes[3].

Other names: Stromal antigen 3SA-3Cohesin subunit SA-3STAG3

Mechanism of action

Not applicable. No therapies or direct pharmacological agents target this protein.

Biological functions

Sister chromatid cohesion during meiosisChromosome axis organization and chromosome synapsisMeiotic homologous chromosome pairing and segregationMaintenance of fertility and gametogenesis (oogenesis and spermatogenesis)Post-transcriptional regulation of gene expression (emerging/mechanistic evidence in stem cells)

Disease associations

Infertility / Reproductive failure (female: premature ovarian failure, male: non-obstructive azoospermia)Cancer (STAG proteins are recurrently mutated in cancer, but direct STAG3 disease roles are mainly infertility)Other (potential epigenetic and stem cell differentiation roles based on recent non-canonical activity)

Safety considerations

None reported in therapeutic context, as there are no drugs currently targeting STAG3. Germline or somatic loss-of-function causes infertility, but there is no evidence of on-target drug safety challenges

Biomarkers

Loss-of-function mutations in STAG3 are used in genetic diagnostics for primary ovarian failure or non-obstructive azoospermia

Beyond the preview

Go deeper on Cohesin subunit SA-3 (STAG3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cohesin subunit SA-3 (STAG3).

Explore the full profile